Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEGAS: PF-04523655 versus laser therapy in diabetic macular edema
2008-000349-68Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2008
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of PF-04523655 in diabetic macular edema (DME) (4 arms), sponsored by Pfizer. Primary endpoint: Change in best corrected visual acuity at 24 months. Started Jun 2008; status: terminated.
02
Drugs
PF-04523655
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2008-000349-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000349-68.